❌

Normal view

A Large-Scale Multimodal Dataset and Benchmarks for Human Activity Scene Understanding and Reasoning

arXiv:2512.07136v1 Announce Type: cross Abstract: Multimodal human action recognition (HAR) leverages complementary sensors for activity classification. Beyond recognition, recent advances in large language models (LLMs) enable detailed descriptions and causal reasoning, motivating new tasks: human action understanding (HAU) and human action reasoning (HARn). However, most LLMs, especially large vision language models (LVLMs), struggle with non-RGB modalities such as depth, IMU, and mmWave due to the lack of large-scale data-caption resources. Existing HAR datasets mainly provide coarse data-label annotations, which are insufficient to capture fine-grained action dynamics needed for HAU and HARn. We consider two ground-truth pair types: (1) data label (discrete category) and (2) data caption (textual description). Naively generating captions from labels often lacks logical and spatiotemporal consistency. We introduce CUHK-X, a large-scale multimodal dataset and benchmark suite for HAR, HAU, and HARn. CUHK-X contains 58,445 samples covering 40 actions performed by 30 participants across two indoor environments. To improve caption consistency, we propose a prompt-based scene creation method that leverages LLMs to generate logically connected activity sequences, followed by human validation. CUHK-X includes three benchmarks with six evaluation tasks. Experiments report average accuracies of 76.52% (HAR), 40.76% (HAU), and 70.25% (HARn). CUHK-X aims to enable the community to apply and develop data-intensive learning methods for robust, multimodal human activity analysis. Project page and code: https://openaiotlab.github.io/CUHK-X/ and https://github.com/openaiotlab/CUHK-X.

Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma

30 May 2025 at 18:00

Front Oncol. 2025 May 15;15:1520733. doi: 10.3389/fonc.2025.1520733. eCollection 2025.

ABSTRACT

Circulating tumor DNA (ctDNA), a subset of cell-free DNA (cfDNA), originates from primary tumors and metastatic lesions in cancer patients, often carrying genomic variations identical to those of the primary tumor. ctDNA analysis via liquid biopsy has proven to be a valuable biomarker for early cancer detection, minimal residual disease (MRD) assessment, monitoring tumor recurrence, and evaluating treatment efficacy. However, despite advancements in ctDNA analysis technologies, standardized protocols for its extraction and detection have yet to be established. Each step of the process-from pre-analytical variables to detection techniques-significantly impacts the accuracy and reliability of ctDNA analysis. This review examines recent developments in ctDNA detection methods, focusing on pre-analytical factors such as specimen types, collection tubes, centrifugation protocols, and storage conditions, alongside high-throughput and ultra-sensitive detection technologies. It also briefly discusses the clinical potential of liquid biopsy in nasopharyngeal carcinoma (NPC).

PMID:40444084 | PMC:PMC12119280 | DOI:10.3389/fonc.2025.1520733

❌